AstraZeneca vs Thermo Fisher Scientific
AstraZeneca (AZN), health care, and Thermo Fisher Scientific (TMO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
AstraZeneca is worth $283.9B on the stock market and Thermo Fisher Scientific $255.6B: AstraZeneca is valued at 11% more. AstraZeneca trades at 25.9 times earnings and Thermo Fisher Scientific at 36.4; operating margins in their latest fiscal years were 23.4% and 17.4%. Over the past year AstraZeneca's share price has moved +2.75% and Thermo Fisher Scientific's +20.0%.
Key facts
- AstraZeneca market value
- $283.9B
- Thermo Fisher Scientific market value
- $255.6B
- AstraZeneca P/E
- 25.9
- Thermo Fisher Scientific P/E
- 36.4
- AstraZeneca revenue
- $58.7BFY to 2025-12-31
- Thermo Fisher Scientific revenue
- $44.6BFY to 2025-12-31
- Superinvestors holding both
- 7
Market values as of .
| Measure | AstraZeneca | Thermo Fisher Scientific |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $283.9Bhigher | $255.6Blower |
| Revenue | $58.7Bhigher | $44.6Blower |
| Earnings | $10.2Bhigher | $6.7Blower |
| Employees | 96,100lower | 125,000higher |
| Total assets | $114.1Bhigher | $110.3Blower |
| Valuation | ||
| P/E | 25.9lower | 36.4higher |
| P/S | 4.8lower | 5.7higher |
| P/B | — | 4.7 |
| Dividend yield | — | 0.27% |
| Profitability | ||
| Operating margin | 23.4%higher | 17.4%lower |
| Balance sheet | ||
| Net assets | $48.7Blower | $53.4Bhigher |
| Total liabilities | $65.4Bhigher | $56.8Blower |
| Total debt | $29.6Blower | $39.4Bhigher |
| Cash on hand | $5.7Blower | $9.9Bhigher |
| Price change | ||
| Today | -0.52%lower | -0.23%higher |
| 1 year | +2.75%lower | +20.0%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (7)
- Primecap team1.8% / 0.8%
- Larry Robbins0.7% / 6.3%
- Ken Fisher0.5% / 0.6%
- Temasek0.4% / 2.2%
- Andrew Spokes0.4% / 1.6%
- Steve Cohen0.2% / 0.2%
- Dodge & Cox team<0.1% / 1.1%
AstraZeneca only (5)
- Sarah Ketterer20.2%
- Lew Sanders1.1%
- Brandon Haley1.1%
- Polen Capital team<0.1%
- Rajiv Jain<0.1%
Thermo Fisher Scientific only (17)
- Nick Train12.4%
- Wallace Weitz4.9%
- Jeremy Grantham (co-founder)4.3%
- Andreas Halvorsen2.8%
- Harry Burn2.7%
- Doug Silverman2.0%
- Steven Romick2.0%
- Diamond Hill team1.6%
- John Armitage1.4%
- Daniel Sundheim0.7%
- Tom Gayner0.4%
- Baillie Gifford team0.4%
- Stanley Druckenmiller0.2%
- David Shaw (founder)0.2%
- Ken Griffin0.2%
- Joel Greenblatt0.2%
- Paul Tudor Jones0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": AstraZeneca / Thermo Fisher Scientific). Who owns AZN · Who owns TMO
More on AstraZeneca
Further comparisons
AstraZeneca against its closest peers
Thermo Fisher Scientific against its closest peers
Learn
Questions and answers
Which is bigger, AstraZeneca or Thermo Fisher Scientific?
By market value, AstraZeneca is the larger: $283.9B against $255.6B for Thermo Fisher Scientific. By revenue in its latest fiscal year, AstraZeneca is the larger: $58.7B against $44.6B for Thermo Fisher Scientific.
Which has the higher P/E ratio?
Thermo Fisher Scientific: 36.4, against 25.9 for AstraZeneca. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
AstraZeneca: 23.4%, against 17.4% for Thermo Fisher Scientific. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Thermo Fisher Scientific: $39.4B, against $29.6B for AstraZeneca. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both AstraZeneca and Thermo Fisher Scientific?
In their latest 13F filings, Primecap team, Larry Robbins, Ken Fisher, Temasek, Andrew Spokes, Steve Cohen and Dodge & Cox team hold both.
Cite this page
Funkfolio, “AstraZeneca vs Thermo Fisher Scientific”, data as of 17 November 2026. https://funkfolio.com/compare/azn-vs-tmo
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.